Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.


In 2002 results of two-phase II studies with the new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib showed not only promising efficacy in second and third line non-small cell lung cancer (NSCLC) therapies but also an excellent tolerability. Since then, thousands of patients have been treated in one of the largest expanded… (More)
DOI: 10.1016/j.lungcan.2010.01.017

5 Figures and Tables


  • Presentations referencing similar topics